QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$43.36 USD
-2.03 (-4.47%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $43.41 +0.05 (0.12%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
QDEL 43.36 -2.03(-4.47%)
Will QDEL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for QDEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QDEL
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod
QDEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
QuidelOrtho (QDEL) Up 3.8% Since Last Earnings Report: Can It Continue?
QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down
QuidelOrtho (QDEL) Reports Q2 Loss, Tops Revenue Estimates
Other News for QDEL
QuidelOrtho Corp (QDEL) Stock Price Down 4.21% on Sep 25
Cracking The Code: Understanding Analyst Reviews For QuidelOrtho
Five Below downgraded, DoorDash upgraded: Wall Street's top analyst calls
QuidelOrtho assumed with Neutral from Sell at UBS
Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc.